Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 5/20 | 0.45 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.45 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122069 | 0.88 | PTGS2 (0.55) | USP1STIM1ORAI1PTGS2CYP2C9 | |
| SCHEMBL6100393 | 0.87 | CDK8 (0.43) | PTGS2MAPT | |
| SCHEMBL15307368 | 0.84 | PTGS2 (0.56) | USP1STIM1ORAI1PTGS2PDPK1 | |
| SCHEMBL25297931 | 0.82 | PDPK1 (0.54) | USP1STIM1ORAI1PTGS2PDPK1 | |
| SCHEMBL18865512 | 0.82 | KLKB1 (0.49) | USP1STIM1ORAI1PTGS2PDPK1 | |
| SCHEMBL22122063 | 0.82 | USP1 (0.48) | USP1STIM1ORAI1PTGS2CYP2C9 | |
| SCHEMBL14504439 | 0.82 | PTGS2 (0.63) | PTGS2PDPK1CYP2C9PTGS1 | |
| SCHEMBL25235132 | 0.81 | CYP2C9 (0.65) | STIM1ORAI1PTGS2CYP2C9PTGS1 | |
| SCHEMBL31566340 | 0.80 | STIM1 (0.46) | STIM1ORAI1PTGS2PDPK1CYP2C9 | |
| SCHEMBL6098089 | 0.80 | MAPT (0.50) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | USP1 3865/4885STIM1 1092/4885ORAI1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.